We propose that a deeper understanding of the relationship between mifepristone and adiponectin signaling in adipose tissue may lead to the identification of novel therapeutic targets in obesity-induced T2DM along with other potentially related pathophysiological conditions, including breast cancer and metabolic diseases. Here, ADIPOQ is linked to metabolic disease.